These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25216543)

  • 1. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is continuous infusion of imipenem always the best choice?
    Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
    Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
    Sakka SG; Glauner AK; Bulitta JB; Kinzig-Schippers M; Pfister W; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3304-10. PubMed ID: 17620371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.
    Jaruratanasirikul S; Sudsai T
    J Antimicrob Chemother; 2009 Mar; 63(3):560-3. PubMed ID: 19153079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H; Lv Y; Wang D; Xue J; Yan Z
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.
    Jaruratanasirikul S; Raungsri N; Punyo J; Sriwiriyajan S
    J Antimicrob Chemother; 2005 Dec; 56(6):1163-5. PubMed ID: 16234333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
    Couffignal C; Pajot O; Laouénan C; Burdet C; Foucrier A; Wolff M; Armand-Lefevre L; Mentré F; Massias L
    Br J Clin Pharmacol; 2014 Nov; 78(5):1022-34. PubMed ID: 24903189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Wongpoowarak W; Nawakitrangsan M; Samaeng M
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):735-747. PubMed ID: 32886347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia.
    Harada M; Inui N; Suda T; Nakamura Y; Wajima T; Matsuo Y; Chida K
    Int J Antimicrob Agents; 2013 Aug; 42(2):149-54. PubMed ID: 23684002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
    Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
    Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.
    Fish DN; Teitelbaum I; Abraham E
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2421-8. PubMed ID: 15917542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective determination of plasma imipenem concentrations in critically ill children.
    Giannoni E; Moreillon P; Cotting J; Moessinger A; Bille J; Décosterd L; Zanetti G; Majcherczyk P; Bugnon D
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2563-8. PubMed ID: 16801447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.